Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

38.31 -0.16 (-0.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022
From Exelixis, Inc.
Via Business Wire
Nasdaq Bear Market: 3 Surefire Growth Stocks to Buy to End the Year Right
Investors can end the year on a high note by scooping up shares of these bargain-basement-priced growth stocks. 
Via The Motley Fool
The Smartest Stocks to Buy With $20 Right Now
You don't need a mountain of cash to begin building wealth on Wall Street. 
Via The Motley Fool
2 No-Brainer Stocks to Buy Right Now for Less than $20
These stocks are still bargain-priced but benefit from long-term trends. 
Via The Motley Fool
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
From Exelixis, Inc.
Via Business Wire
What 4 Analyst Ratings Have To Say About Exelixis
Exelixis (NASDAQ:EXEL) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Exelixis Inks Two Licensing Pacts For Cancer Programs
 
Via Benzinga
Exelixis (EXEL) Q3 2022 Earnings Call Transcript
EXEL earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Here's Why This Growth Stock Is Already My 2022 Winner
Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter. 
Via The Motley Fool
Looking Into Exelixis's Return On Invested Capital
Pulled from Benzinga Pro data, Exelixis (NASDAQ:EXEL) posted Q3 earnings of $73.21 million, an increase from Q2 of 3.59%. Sales dropped to $411.74 million, a 1.83% decrease between quarters. 
Via Benzinga
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
From Exelixis, Inc.
Via Business Wire
Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer
 
Via Benzinga
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Nasdaq Bear Market: 5 Magnificent Growth Stocks You'll Regret Not Buying on the Dip
With the Nasdaq Composite down as much as 38% from its peak, these highly innovative companies are ripe for the picking. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
2 Top Biotech Stocks to Buy for the Long Haul
Both drugmakers have outperformed the market in the past year. 
Via The Motley Fool
Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022
From Exelixis, Inc.
Via Business Wire
Worried About Rising Interest Rates? These 2 Growth Stocks Could Offer a Solution
These stocks have low-to-no debt, and analysts see tons of upside. 
Via The Motley Fool
Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022
From Exelixis, Inc.
Via Business Wire
The Smartest Stocks to Buy With $20 Right Now
Cheap stocks have the ability to generate enormous, long-term profits for investors. 
Via The Motley Fool
These 7 Biotech Stocks Are Set to Boom in 2023
This article looks at seven biotech stocks that look like good options to move significantly higher in 2023 
Via InvestorPlace
Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial
From Exelixis, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022
Upgrades 
Via Benzinga
3 Biotech Stocks to Buy Now for Extraordinary Gains
These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market. 
Via InvestorPlace
Exelixis' XL092/ Atezolizumab Shows Encouraging Efficacy, Safety In Heavily Pretreated Cancer Patients
 
Via Benzinga
Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022
From Exelixis, Inc.
Via Business Wire
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS